Enhanced immune response in bovine species

a bovine and immune-boosting technology, applied in the field of bovine immune activation in a member of the bovine species, can solve the problems of loss of milk production, negative impact on carcass characteristics, and current vaccination programs and pharmaceutical therapies are not optimal

Inactive Publication Date: 2013-11-07
BAYER INTELLECTUAL PROPERTY GMBH
View PDF8 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These losses are due to morbidity, mortality, reduced weight gains, treatment and prevention costs, loss of milk production, and negative impacts on carcass characteristics.
There are different reasons why current vaccination programs and pharmaceutical therapies are not optimal to control BRD in cattle today.
However, the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Evaluation of Cattle Receiving a DNA Immunomodulator Before or After Developing Natural Bovine Respiratory Disease

[0078]The purpose of this study was to determine the efficacy of the DNA immunomodulator administered to calves prior to and after developing natural cases of BRD.

Immunomodulator

[0079]The immunomodulator used in this study was a composition comprising a cationic lipid and non-coding DNA. The synthetic immunomodulator lipid components [1-[2-[9-(Z)-octadecenoyloxy]]-2-[8](Z)-heptadecenyl]-3-[hydroxyethyl]imidazolinium chloride (DOTIM) and a synthetic neutral lipid cholesterol were formulated to produce liposomes approximately 200 nm in diameter (See, U.S. Pat. No. 6,693,086). The DNA component was a 4242 base-pair non-coding DNA plasmid produced in E. coli, which, being negatively charged, associates with the positively-charged (cationic) liposomes (See, U.S. Pat. No. 6,693,086).

Study Animals

[0080]84 Holstein steer calves of weaning age were selected from a herd without a ...

example 2

Evaluation of Cattle Receiving a DNA Immunomodulator Concurrently with or One Day After an Experimental Challenge with Mannheimia haemolytica

[0091]The purpose of this study was to determine the efficacy of the DNA immunomodulator administered to calves concurrently with or one day after an experimental challenge with Mannheimia haemolytica.

Immunomodulator

[0092]The immunomodulator used in this study was the composition described above in Example 1.

Study Animals

[0093]84 Holstein steer calves of weaning age and weighing on average about 300 lbs (136 kg) were selected from a herd without a current history of respiratory disease. Each individual calf was initially evaluated and determined to be in good health. The 84 calves were divided into seven treatment groups of 12 calves each. Only animals not vaccinated for Mannheimia haemolytica were included in the study. None of the animals had received an antimicrobial agent within 30 days prior to administration of DNA immunomodulator. The ...

example 3

Evaluation of Cattle Receiving a DNA Immunomodulator Two Days Before or Concurrently with an Experimental Challenge with Mannheimia haemolytica

[0103]The purpose of this study was to determine the efficacy of the DNA immunomodulator administered to calves two days before or concurrently with an experimental challenge with Mannheimia haemolytica.

Immunomodulator

[0104]The immunomodulator used in this study was the composition described above in Example 1.

[0105]Study Animals

[0106]96 Holstein steer calves weighing on average about 800-1000 lbs (363-454 kg) were selected from a herd without a current history of respiratory disease. Each individual calf was initially evaluated and determined to be in good health. The 96 calves were divided into eight treatment groups of 12 calves each. Only animals not vaccinated for Mannheimia haemolytica were included in the study. None of the animals had received an antimicrobial agent within 30 days prior to administration of DNA immunomodulator. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a method of immune activation in a member of the bovine species. In particular, the present invention includes methods for eliciting systemic, non-specific and antigen-specific immune responses, which are useful for animal administration and protection against infectious disease.BACKGROUND OF THE INVENTION[0002]Cattle are prime targets for many types of viral, bacterial, and parasite infections. Modern production practices, such as weaning, shipment of cattle, inclement weather, and nutritional needs within the beef and dairy industries may also serve as risk factors that potentiate the incidence of disease. Bovine respiratory disease (BRD), or bovine respiratory diseases complex, as it is often referred to, occurs in both dairy and beef cattle and is one of the leading causes of economic loss to the cattle industry throughout the world. These losses are due to morbidity, mortality, reduced weight gains, treatment and prev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/39
CPCA61K39/39A61K9/0019A61K9/1272A61K31/711A61K39/102A61K45/06A61K2039/55555A61K2039/55566A61P11/00A61P31/04A61P31/12A61P37/02A61P37/04A61P43/00A61K39/00A61K47/50A61K9/127A61K2039/552A61K9/1271
Inventor ABRAHAM, ALBERTKEIL, DANIELNICKELL, JASONWEISS, CHRISTIAN
Owner BAYER INTELLECTUAL PROPERTY GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap